see benefits of the flexpen

 

 

NovoLog® FlexPen®: A dial-a-dose insulin pen that is proven accurate

   

shadow

NovoLog® FlexPen® is the #1-selling, pre-filled, rapid-acting insulin pen in the world1

Benefits of NovoLog® FlexPen® pre-filled insulin pen


aNeedles are sold separately and may require a prescription in some states.



 

FlexPen® offers many benefits

  • Teachable, learnable, usable
  • Proven accuracy3
  • Discreet—fits neatly in your patient’s purse or pocket
  • Covered for more than 95% of managed careb patients nationwide4
  • Patients who use FlexPen® may get 50% more insulin with each prescription (1,500 units in a box of 5 pens, compared to 1,000 units in a vial)

bManaged care plans only. Does not include Medicaid and Medicaid Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status is subject to change.

 



 

Can be used with NovoTwist® or NovoFine® Needles

NovoTwist®– introducing the first single-twist needle

  • “Just Twist” injection needle with a bayonet fitting
  • Less time-consuming for patients to attach
  • Audible and tactile confirmatory click for correct attachment
  • Available for 32G Tip (5 mm) needles
mechanism of how novotwist and novofine needles work

NovoFine® Needles

  • NovoFine® needles fit all major insulin devices
  • NovoFine® 32G Tip with SuperFlow™ Technology designed to enhance flow rate and reduce dosing force when injecting
  • Little or no painc - A majority of patients using the NovoFine® 32G Tip needle experienced almost no painc
  • NovoLog® FlexPen® uses NovoFine® disposable needles, designed to help improve injection comfort
description of NovoFine® needles

Needles are sold separately and may require a prescription in some states. Never share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® cartridge, or PenFill® cartridge device between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.

cMulticenter, randomized, open-label, 2-period, crossover trial in insulin-treated patients with diabetes (type 1 or type 2). Patients were randomized to self administer insulin injections with one needle type followed by the alternative, each for 7 to 14 days. The 2 needle types used were NovoFine® 32-gauge tip x 6 mm and NovoFine® 30-gauge tip x 8 mm.4
 



 

NovoLog® FlexPen®: stable in storage

chart showing how novolog FlexPen® is stable in storage

dPenFill® cartridges in use (opened) must NOT be stored in the refrigerator.
eVials in use (opened) may be stored in the refrigerator until the label expiration date.

 

Broad Formulary Access

Learn about NovoLog® FlexPen® coverage in your area.


 

learn about novolog FlexPen® in your area


 


Get insights from experts

Thought leaders talk about bolus insulin therapy, from the role of PPG control in helping to reach A1C goals to improving patient engagement.

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.

 

References

  1. Quintiles IMS – MIDAS (12 months ending February 2017).
  2. Pfützner A, Reimer T, Hohberg C, Frøkjær LPF, Jørgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545-2549.
  3. Data on file. Novo Nordisk, Inc., Plainsboro, NJ.
  4. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perception of pain, handling, and acceptability: A randomized, open-label, crossover study in subjects with diabetes. Diabetes Tech. 2009;11(3)195-201.